Filing Details
- Accession Number:
- 0001181431-11-047703
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-09-01 16:06:23
- Reporting Period:
- 2011-08-30
- Filing Date:
- 2011-09-01
- Accepted Time:
- 2011-09-01 16:06:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 820096 | Perrigo Co | PRGO | Pharmaceutical Preparations (2834) | 382799573 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1398276 | Thomas Farrington | C/O Perrigo Company 515 Eastern Avenue Allegan MI 49010 | Senior Vp And Cio | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-08-30 | 1,956 | $20.50 | 3,859 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-08-30 | 600 | $94.01 | 3,259 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2011-08-30 | 700 | $95.35 | 2,559 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2011-08-30 | 656 | $96.27 | 1,903 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option Right to Buy | Disposition | 2011-08-30 | 1,956 | $0.00 | 1,956 | $20.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2011-08-30 | 2017-08-30 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1sales plan adopted by the reporting person on March 4, 2011. This 10b5-1 sales plan will expire on the close of business February 16, 2012.
- The price in column 4 is a weighted average. The prices actually received ranged from $93.69 to $94.54. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- The price in column 4 is a weighted average. The prices actually received ranged from $94.94 to $95.85. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- The price in column 4 is a weighted average. The prices actually received ranged from $95.95 to $96.62. For all transactions reported in this Form 4 utilizing a weighted average price, the reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
